Shopping Cart
Remove All
Your shopping cart is currently empty
Botensilimab (AGEN 1181) is a humanized monoclonal antibody that specifically targets cytotoxic T-lymphocyte antigen 4 (CTLA-4). Botensilimab (AGEN 1181) functions as a potent activator of both innate and adaptive immune responses. Botensilimab (AGEN 1181) is under active research for its capacity to enhance antitumor immunity and modulate checkpoint pathways.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $213 | - | In Stock | |
| 5 mg | $562 | - | In Stock | |
| 10 mg | $893 | - | In Stock | |
| 25 mg | $1,320 | - | In Stock | |
| 50 mg | $1,780 | - | In Stock |
| Description | Botensilimab (AGEN 1181) is a humanized monoclonal antibody that specifically targets cytotoxic T-lymphocyte antigen 4 (CTLA-4). Botensilimab (AGEN 1181) functions as a potent activator of both innate and adaptive immune responses. Botensilimab (AGEN 1181) is under active research for its capacity to enhance antitumor immunity and modulate checkpoint pathways. |
| In vitro | The Fc region of Botensilimab has improved properties that allow for more efficient binding to Fcγ receptors on antigen-presenting cells and natural killer cells [1]. |
| Synonyms | AGEN1181, AGEN 1181 |
| Cas No. | 2408310-37-0 |
| Color | Transparent |
| Appearance | Liquid |
| Storage | store at low temperature | store at -20°C | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.